Lung Diseases, Interstitial Clinical Trial
Official title:
Non-invasive Ventilation in Patients With Interstitial Lung Disease - a Feasibility Study
NCT number | NCT02377739 |
Other study ID # | NIV-ILD |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2015 |
Est. completion date | December 2019 |
The efficiency of non-invasive ventilation (NIV) in hypercapnic patients with chronic obstructive pulmonary disease during pulmonary rehabilitation has been shown in numerous studies. There is only a limited number of therapeutic options for patients with severely progressed interstitial lung disease (ILD). The question whether chronic hypercapnic ILD-patients are able to profit from nocturnal NIV and thus increase their performance in physical training has been left unknown. Therefore, this study aims to evaluate the feasibility of the initialization of a NIV for hypercapnic ILD-patients during pulmonary rehabilitation.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2019 |
Est. primary completion date | October 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - confirmed diagnosis of Interstitial lung disease - Hypercapnia defined as carbon dioxide partial pressure =45 mmHg (at rest, night or activity) - already existing but not sufficient and regular use of non-invasive ventilation (=3h/24h) - patients consent to participate in this trial Exclusion Criteria: - acute pulmonary insufficiency (ph<7.35) - acute, clinically relevant heart disease - already existing and sufficient use of non-invasive ventilation (=3h/24h) - Body-Mass-Index>30 - obstructive sleep apnea - Intolerance to perform non-invasive ventilation - acute infection |
Country | Name | City | State |
---|---|---|---|
Germany | Schoen Klinik Berchtesgadener Land | Schoenau Am Koenigssee | Bayern |
Lead Sponsor | Collaborator |
---|---|
Klinikum Berchtesgadener Land der Schön-Kliniken | Weinmann Geräte für Medizin GmbH + Co. KG |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | timespan until sufficient use of noninvasive ventilation > 6h during night | day 4-16 | ||
Secondary | 6-minute walking test | change in 6-minute walking distance | day 1-3 and day 17-19 | |
Secondary | arterial pressure of carbon dioxide during night | measured transcutaneously by a Sentec device | day 1-3 and day 17-19 | |
Secondary | lung function measured by bodyplethysmograph | measured by bodyplethysmograph | day 1-3 and 17-19 | |
Secondary | energy expenditure during night assessed by Sensewear Armband | assessed by Sensewear Armband | day 5 and 15 | |
Secondary | quality of life | Short-Form-36 health survey, Hospital Anxiety and Depression scale and severe respiratory insufficiency questionnaire | day 1-3 and 17-19 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04119115 -
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
|
||
Active, not recruiting |
NCT04559581 -
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
|
||
Recruiting |
NCT05151640 -
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
|
||
Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT02251964 -
Rituximab in Interstitial Pneumonitis
|
Phase 2/Phase 3 | |
Terminated |
NCT01432080 -
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
|
Phase 2 | |
Completed |
NCT01442779 -
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT05866198 -
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
|
N/A | |
Active, not recruiting |
NCT05321082 -
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
|
Phase 3 | |
Completed |
NCT04016168 -
Idiopathic Pulmonary Fibrosis and Serum Bank
|
||
Recruiting |
NCT00258583 -
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
|
||
Recruiting |
NCT05855109 -
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
|
||
Completed |
NCT05719233 -
Assessment of Neuropsychiatric Function in Patients With Interstitial Lung Disease
|
||
Recruiting |
NCT04159129 -
Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
|
||
Completed |
NCT03313180 -
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
|
Phase 3 | |
Completed |
NCT05065190 -
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
|
Phase 3 | |
Completed |
NCT03136120 -
Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
|
||
Recruiting |
NCT04930666 -
BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease
|
||
Recruiting |
NCT05503030 -
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
|